Pacific Biosciences Of California traded at $1.68 this Thursday July 2nd, decreasing $0.07 or 3.74 percent since the previous trading session. Looking back, over the last four weeks, Pacific Biosciences Of California lost 6.01 percent. Over the last 12 months, its price rose by 4.69 percent. Looking ahead, we forecast Pacific Biosciences Of California to be priced at 1.62 by the end of this quarter and at 1.52 in one year, according to Trading Economics global macro models projections and analysts expectations.
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include the Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together are capable of sequencing up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together are capable of sequencing up to one million DNA molecules simultaneously. Its Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.